Technology | Nuclear Imaging | January 16, 2019

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry

MIM SurePlan MRT provides quantitative SPECT reconstruction and voxel-based absorbed dose calculation for molecular radiotherapy

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry

January 16, 2019 — MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy (MRT) dosimetry.

MRT is an effective form of therapy that uses radiopharmaceuticals such as Lutathera (Lu-177 DOTATATE) and Azedra (I-131 iobenguane) to target tumors based on certain receptors that these tumors express.

Until now, there has not been an effective way to measure the absorbed dose from MRT for an individual patient. This is due to a lack of access to quantitative single photon emission computed tomography (SPECT) images and tools for calculating dose on the patient's own anatomy. MIM SurePlan MRT provides both quantitative SPECT reconstruction and voxel-based absorbed dose calculation by utilizing the patient's own images, allowing for personalized dosimetry measurements.

MIM SurePlan MRT provides timesaving tools for organ and tumor segmentation, deformable registration and voxel-based dosimetry for molecular radiotherapy. Other features of MIM SurePlan MRT include multi-tracer theranostics support, quantitative SPECT and planar corrections, and dosimetry reporting tools.

MIM Software will demonstrate MIM SurePlan MRT at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Mid-Winter Meeting, Jan. 18-19 in Palm Springs, Calif.

For more information: www.mimsoftware.com

Related Content

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Nuclear imaging of the spine shown on Philips Healthcare BrightView XCT

Image courtesy of Philips Healthcare

News | Nuclear Imaging | January 27, 2020
January 27, 2020 — According to the new market research report "...
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Feature | Radiation Oncology | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 20 pieces of radiation oncology content on the Imaging Technology News (ITN) websit
Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by an AI algorithm from RaySearch and is the subject of the No. 2 video on the list. Deep learning in radiology and radiation oncology.

Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by a machine learning algorithm from RaySearch and is the subject of the No. 2 video on the list. 

Feature | December 30, 2019
Here are the top 20 best performing videos posted on the Imaging Technology News website (ITN) from the past year, ba
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...
Beamscan MR for ViewRay MRIdian and for Elekta Unity

Beamscan MR for ViewRay MRIdian and for Elekta Unity

News | Radiation Therapy | December 23, 2019
December 23, 2019 — The Beamscan MR motorized 3-D...
radiation exposure triggers an immune response in the brain that severs connections between nerve cells
News | Clinical Trials | December 17, 2019
December 17, 2019 — One of the potentially life-altering side effects that patients experience after...
In connection with the collaboration, Elekta has committed to make an investment in ViewRay representing approximately 9.9 percent of the shares of ViewRay’s common stock
News | Radiation Therapy | December 13, 2019
December 13, 2019 — Elekta announced that the company has sign